Cybin (HELP) Liabilities and Shareholders Equity (2021 - 2026)
Cybin (HELP) posted quarterly Liabilities and Shareholders Equity of $251.2 million for Q1 2026, up 39.35% year-on-year from $180.2 million in Q1 2025, and down 13.42% on a QoQ basis from $290.1 million in Q4 2025.
Cybin (HELP) Liabilities and Shareholders Equity (2021 - 2026) Analysis & Trends
Cybin (HELP) has reported Liabilities and Shareholders Equity for 6 consecutive years, with $251.2 million the latest figure, recorded in Q1 2026.
- Quarterly Liabilities and Shareholders Equity rose 39.35% year-over-year to $251.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $933.3 million (up 22.45% YoY) and the FY2026 annual result came in at $251.2 million, up 35.01% from the prior year.
- Liabilities and Shareholders Equity eased to $251.2 million in Q1 2026 per HELP's latest filing, from $290.1 million in the prior quarter.
- Over the last five years, Liabilities and Shareholders Equity for HELP reached as high as $290.1 million in Q4 2025 and fell as low as $33.8 million in Q1 2023.
- A 5-year average of $149.8 million and a median of $181.2 million in 2025 frame the typical range for Liabilities and Shareholders Equity.
- Annual changes were most pronounced in 2022 — Liabilities and Shareholders Equity tumbled 40.77% — and 2024, when it jumped 347.47%.
- Year by year, Liabilities and Shareholders Equity stood at $44.7 million in 2022, then surged by 113.11% to $95.3 million in 2023, then soared by 90.48% to $181.5 million in 2024, then soared by 59.84% to $290.1 million in 2025, then declined by 13.42% to $251.2 million in 2026.
- According to Business Quant data, Liabilities and Shareholders Equity over the past three periods registered $251.2 million, $290.1 million, and $181.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 311.58 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 78.88 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 8.55 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 39.68 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 26.48 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 40.87 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | 811.27 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 10.03 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 2.25 Bn |
| 10 | Cybin | 28.04 Mn | 28.04 Mn | - | 251.17 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 251.17 Mn |
| Dec 31, 2025 | 290.11 Mn |
| Sep 30, 2025 | 181.25 Mn |
| Jun 30, 2025 | 210.81 Mn |
| Mar 31, 2025 | 180.24 Mn |
| Dec 31, 2024 | 181.50 Mn |
| Sep 30, 2024 | 192.35 Mn |
| Jun 30, 2024 | 208.12 Mn |
| Mar 31, 2024 | 224.14 Mn |
| Dec 31, 2023 | 95.29 Mn |
| Sep 30, 2023 | 42.99 Mn |
| Jun 30, 2023 | 57.54 Mn |
| Feb 28, 2023 | 33.80 Mn |
| Dec 31, 2022 | 44.71 Mn |
| Sep 30, 2022 | 52.99 Mn |
| Dec 31, 2021 | 75.49 Mn |
| Sep 30, 2021 | 83.78 Mn |
| Jun 30, 2021 | 67.39 Mn |
| Mar 31, 2021 | 72.78 Mn |